NeVa NET
Acute Ischemic Stroke
Development/CommercialActive
Key Facts
About Vesalio
Vesalio is a private, commercial-stage medical device company developing novel thrombectomy technologies for acute vascular occlusions across multiple territories, including stroke, heart attack, and peripheral arterial disease. Its core innovation is the patented Drop Zone technology, designed to improve first-pass success and clot retention. The company has achieved significant regulatory milestones, including FDA clearance and CE Mark for its flagship products, positioning it in large, high-need cardiovascular markets.
View full company profileOther Acute Ischemic Stroke Drugs
| Drug | Company | Phase |
|---|---|---|
| Presendin™ (Exenatide) | Invex Therapeutics | Phase 2 |
| Supernova Stent Retriever | Gravity Medical Technology | Commercial |
| Neutron Reperfusion Catheter | Gravity Medical Technology | Commercial |
| AST-004 | Astrocyte Pharmaceuticals | Phase 1/2 |
| scp776 | Silver Creek Pharmaceuticals | Phase 2 |
| VB-001 | VST Bio | Pre-clinical |
| Pulse NanoMED for AIS | Euphrates Vascular | Pre-clinical |
| ApTOLL | aptaTargets | Phase 2 |
| ThermoSuit® for Acute Ischemic Stroke | Life Recovery Systems HD | Pivotal Trial (Planned) |
| Pulsante for Ischemic Stroke | Realeve | Research/Clinical Study |
| Glenzocimab (ACT017) | Acticor Biotech | Phase 2/3 |
| eTrieve™ Microcatheter | Magneto Thrombectomy Solutions | Phase 1 |